Preparation and in vitro evaluation of B-lipiodol as a boron delivery agent for neutron capture therapy of hepatoma

Anticancer Research

Volumn 19, Issue 3 A, 1999, Pages 1759-1764

  Chou, Fong I N ^a   Lui, Wing Yiu ^a   Wei, Yuan Yaw ^a   Chung, Ren Jei ^a   Kai, J I Jung ^a   Chi, Chin Wen ^a  

^a NONE

Author keywords

B lipiodol; Hepatoma; Neutron capture therapy

Indexed keywords

BORON; IODINATED POPPYSEED OIL;

ARTICLE; ATOMIC EMISSION SPECTROMETRY; CELL TRANSPORT; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROSCOPE; NEUTRON ACTIVATION ANALYSIS; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; SERUM;

ANIMALS; BORON; BORON NEUTRON CAPTURE THERAPY; CARCINOMA, HEPATOCELLULAR; DRUG CARRIERS; ENDOCYTOSIS; FEASIBILITY STUDIES; HUMANS; IODIZED OIL; ISOTOPES; LIVER NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032774333     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Nakagawa Y and Hatanaka H: Boron neutron capture therapy clinical brain tumor studies. J Neuro-Oncol 33: 105-115, 1997.
2. Coderre JA, Elowitz EH, Chadha M, Bergland R, Capala J, Joel DD, Liu HYB, Slatkin DN and Chanana AD: Boron neutron capture therapy for glioblasloma multiforme using p-boronophenylalanine and epithermal neutrons trial design and early clinical results. J Neuro-Oncol 33: 141-152, 1997.
3. Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, and Wilson JG: The chemistry of neutron capture therapy. Chem. Rev. 98:1515-1562, 1998.
4. Barth RF, Yang WL, Rotaru JH, Moeschberger ML, Joel DD, Nawrocky MM, Goodman JH and Soloway AH: Boron neutron capture therapy of brain tumors enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood brain barrier disruption. Cancer Res 57: 1129-1136, 1997.
5. Fairchild RG, Kahl SB, Laster BH, Kalefezra J and Popenoe EA: In vitro determination of uptake, retention, distribution, biological efficacy, and toxicity of boronated compounds for neutron capture therapy: a comparison of porphyrins with sulfhydryl boron hydrides. Cancer Res 50: 4860-4865, 1990.
6. Liu L, Barth RF, Tjarks W, Soloway AH and Anisuzzaman AKM: In vitro and in vivo evaluation of carboranyl uridines as boron delivery agents for neutron-capture therapy. Anticancer Res 16: 113-120, 1996.
7. Sjoberg S, Carlsson J, Ghaneolhosseini H, Gedda L, Hartman T, Malmquist J, Naeslund C, Olsson P and Tjarks W: Chemistry and biology of some low molecular weight boron compounds for boron neutron capture therapy. J Neuro-Oncol 33: 41-52, 1997.
8. Olsson P, Black M, Capala J, Coderre J, Hartman T, Makar M, Malmoquist J, Pettersson J, Tilly N, Sjoberg S and Carlsson J: Uptake, toxicity and radiation effects of the boron-compounds Daac-1 and DAC-1 in cultured human glioma-cells. Int J Radiat Biol 73: 103-112, 1998.
9. Allen BJ, Wallace SA and Carolan MG: Can epithermal boron neutron capture therapy treat primary and metastatic liver cancer? In: Larsson B, Crawford J, and Weinreich R (eds) Advances in'Neutron Capture Therapy Volume I, Medicine and Physics pp 118-212, 1997.
10. Killion JJ and Fidler IJ: Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. Pharmacol Therapeut 78: 141-154, 1998.
11. Codde JP, Lumsden AJ, Napoli S, Burton MA and Gray BN: A comparative study of the anticancer efficacy of doxorubicin carrying microspheres and liposomes using a rat liver tumor model. Anticancer Res 13: 539-543, 1993.
12. Kamio Y, Toda T, Tanaka R, Sasaki S, Kishikawa T, Ito J, Kato T and Kato H: Enhancement of both intracellular uptake and antitumor action of cisplatinum on human neuro-blastoma cells by encapsulation in liposomes. Jpn J Cancer Res 80: 787-793,1989.
13. Maki S, Maeda H and Konno T: Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 56: 751-757, 1985.
14. Maini CL, Scelsa MG, Tofani A, Sciuto R, Tipaldi L, Dannibale M and Santoro E: Superselective intraarterial radiometabolic therapy with I-131 lipiodol in hepatocellular-carcinoma. Clin Nucl Med 21: 221-226, 1996.
15. Nishizaki T, Takenaka K, Yanaga K, Kishikawa K, Maehara Y, Shimada M and Sugimachi K: Sensitivity of hepatocellular-carcinoma to 9 anticancer drugs is unchanged after administration of epirubicin suspended in lipiodol. Int J Oncol 8: 1059-1062, 1996.
16. Chou FI, Fang KC, Chung C, Lui WY, Chi CW, Chan WK and Liu RS: Lipiodol uptake and retention by human hepatoma cells. Nucl Med Biol 22; 379-386, 1995.
17. Chou FI, Wei YY, Jeang SJ, Wang TK, Kai JJ, Chi CW and Lui WY: Encapsulation of boron in lipiodol for boron neutron capture therapy of hepatoma. In: Larsson B, Crawford J, and Weinreich R (eds) Advances in Neutron Capture Therapy Volume II, Chemistry and Biology pp101-107, 1997.
18. Chou FI, Lin HD, Wei JC, Wang AY and Lo JG: Simplified measurement of protein-bound iodine with epithermal neutron activation analysis. Nucl Med Biol 20: 631-636, 1993.
19. Park C, Choi S I, Kim H, Yoo HS and Lee YB: Distribution of lipiodol in Hepatocellular carcinoma. Liver 10: 72-78, 1990.
20. 7 Li reaction in HeLa cells. Radiat Res 43: 534-553, 1970.
21. Yoo HS, Lee JT, Kim KW, Kim BS, Choi HJ, Lee KS, Park CI, Park CY, Suh JH and Loh JJK: Nodular hepatocellular carcinoma treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil. Cancer 68: 1878-1884, 1991.
22. Lui WY, Liu RS, Chiang JH, Lo JC, Lai KH, King KL, Cheng HC, Wei YY, Chi CW, Peng FK and Chan WK: Report of a pilot study of intraarterial injection of I-131 lipiodol for the treatment of hepatoma. Chin Med J (Taipei) 46: 125-133, 1991.
23. Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham MC, Mcguffie E, Old LJ and Larson SM: Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med 37: 1052-1057, 1996.